Table 1.
Patient, disease, and first transplant characteristics.
| Subjects | 40 | |
|---|---|---|
| median age (range) | 43.9 (1–74) | |
| Female | 14 | |
| Disease type | ||
| AML | 12 | |
| ALL | 12 | |
| HL | 4 | |
| DLBCL | 2 | |
| MDS | 2 | |
| Biphenotypic acute leukemia | 2 | |
| CML | 2 | |
| CMML | 1 | |
| MM | 1 | |
| MCL | 1 | |
| FL | 1 | |
| First Transplant History | ||
| Conditioning Intensity | ||
| Myeloablative | 17 | |
| Reduced intensity | 3 | |
| Non-myeloablative | 20 | |
| Conditioning Regimens | ||
| Flu/Cy/TBI | 19 | |
| Bu/Cy | 11 | |
| Bu/Flu | 4 | |
| Cy/TT/TBI | 3 | |
| Cy/TBI | 2 | |
| Flu/TBI | 1 | |
| Allograft Match | ||
| Haploidentical | 21 | |
| MSD | 9 | |
| MUD | 7 | |
| Umbilical Cord | 2 | |
| MMUD (9/10) | 1 | |
| GVHD Prophylaxis | ||
| PTCy, Tacrolimus, MMF | 24 | |
| PTCy | 10 | |
| MTX, Tacrolimus | 4 | |
| PTCY, Tacrolimus, Sirolimus | 1 | |
| T cell depletion | 1 | |
| Incidence of GVHD* | ||
| Acute | ||
| none or grade 1 | 34 | |
| grades 2–4 | 5 | |
| grades 3–4 | 1 | |
| Chronic | ||
| none | 34 | |
| limited | 5 | |
| extensive | 0 | |
*
One patient, who received the first transplant at another institution, had GVHD of an unknown type and grade.
MSD – matched sibling donor; MUD – matched unrelated donor; MMUD – mismatched unrelated donor (9/10 HLA matched); PTCy – high-dose posttransplantation cyclophosphamide; MMF – mycophenolate mofetil.